Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10815972 | 0.72 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1RECQLHPGD | |
| SCHEMBL596055 | 0.71 | — | — | |
| SCHEMBL3538058 | 0.70 | MAOB (0.51) | ALDH1A1HPGDPKMMAPTLMNA | |
| SCHEMBL578880 | 0.70 | — | — | |
| SCHEMBL8026459 | 0.69 | SRD5A1 (0.31) | — | |
| SCHEMBL11876056 | 0.68 | MEN1 (0.42) | MEN1KMT2AALDH1A1RECQLHPGD | |
| SCHEMBL8077429 | 0.67 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1RECQLHPGD | |
| SCHEMBL9364601 | 0.66 | KMT2A (0.38) | MEN1KMT2AALDH1A1RECQLHPGD | |
| SCHEMBL6627174 | 0.66 | HPGD (0.49) | MEN1KMT2AALDH1A1RECQLHPGD | |
| SCHEMBL1110850 | 0.66 | GPR84 (0.53) | MEN1KMT2AALDH1A1RECQLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203590-A1 | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE | DIAZYME LABORATORIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9000132-B2 | Lipoprotein-associated phospholipase A2 antibody compositions and methods of use | DIADEXUS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2014144040-A1 | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE | DIADEXUS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275485-A1 | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE | DIADEXUS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140283157-A1 | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE | DIADEXUS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130236450-A1 | Methods Using Lipoprotein-Associated Phospholipase A2 in an Acute Care Setting | MONTANER JOAN (ES) | 2013-09-12 | — | — | US | disclosed |
| EP-1718967-B1 | METHODS OF DETECTING Lp-PLA2 ACTIVITY | DIADEXUS INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2563914-A1 | METHODS USING LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN AN ACUTE CARE SETTING | Diadexus, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011137419-A1 | METHODS USING LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN AN ACUTE CARE SETTING | DIADEXUS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-2280282-A1 | Methods of detecting Lp-PLA2 activity | Diadexus, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-1619196-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| WO-2005074604-A2 | METHODS OF DETECTING Lp-PLA2 ACTIVITY | DIADEXUS, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| EP-1175408-B1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1479671-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040167142-A1 | Pyrimidinone compounds | SMITHKLINE BEECHAM P.L.C. | 2004-08-26 | — | — | US | disclosed |
| EP-1175409-A1 | PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1175408-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000068208-A1 | PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000066567-A1 | PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167142-A1 | Pyrimidinone compounds | LPL, LIPG, PCSK9 | MEN1 3004/4885KMT2A 3219/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.